Abstract:Background Abnormalities of tubulin polymerization and microtubule assembly are often seen in cancer, which make them very suitable targets for the development of therapeutic approach against rapidly dividing and aggressive cancer cells. CYT997 is a novel microtubule-disrupting agent with anticancer activity in multiple cancer types including prostate cancer. However, the molecular mechanisms of action of CYT997 in prostate cancer have not been well characterized. Methods Src knockdown cells were achieved by lentiviral-mediated interference. The drug effects on cell proliferation were measured by MTS. The drug effects on cell viability and death were determined by Cell Titer-Glo® Luminescent cell viability kit and flow cytometry with Zombie Aqua™ staining. The drug effects on apoptosis were assessed by Cell Death Detection Elisa kit and Western blot with a cleaved PARP antibody. The drug effects on cell invasion were examined by Matrigel-coated Boyden chambers. Oxidative stress was detected by DCFH-DA staining and electrochemical biosensor. Mouse models generated by subcutaneous or intracardiac injection were used to investigate the in vivo drug efficacy in tumor growth and metastasis. Results CYT997 effectively inhibited proliferation, survival, and invasion of prostate cancer cells via blocking multiple oncogenic signaling cascades but not the Src pathway. Inhibition of Src expression by small hairpin RNA or inactivation of Src by dasatinib increased the CYT997-induced cytotoxicity of in vitro. Moreover, the combination of dasatinib and CYT997 exhibited a superior inhibitory effect on tumor growth and metastasis compared with either of the drugs alone. Conclusion Our findings demonstrate that blockage of Src augments the anticancer effect of CYT997 on prostate cancer and suggest that co-treatment of dasatinib and CYT997 may represent an effective therapeutic regimen for limiting prostate cancer.

YSY01A, a Novel Proteasome Inhibitor, Induces Cell Cycle Arrest on G2 Phase in MCF-7 Cells Via ERα and PI3K/Akt Pathways

Anticancer Effect of a Novel Proteasome Inhibitor, YSY01A, Via G2/M Arrest in PC-3M Cells in Vitro and in Vivo.

Cell cycle arrest effect of compound YSY-01A, a new proteasome inhibitor,on SK-OV-3 cells

Proteasome Inhibitor Ysy01a Abrogates Constitutive Stat3 Signaling Via Down-Regulation of Gp130 and Jak2 in Human A549 Lung Cancer Cells

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.

cyy-287, a novel pyrimidine-2,4-diamine derivative, inhibits tumor growth of EGFR-driven non-small cell lung cancer via the ERK pathway

SY-707, an ALK/FAK/IGF1R inhibitor, suppresses growth and metastasis of breast cancer cells

Synthesis and Anti-Tumor Activity Evaluation of 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide Derivatives with Phenyl Sulfonamide Groups As Potent RSK2 Inhibitors

Proteasome Inhibitor Ysy01a Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells

Snx-2112, A Novel Hsp90 Inhibitor, Induces G2/M Cell Cycle Arrest and Apoptosis in Mcf-7 Cells

Design, Synthesis and Biological Assessment of N′-(2-Oxoindolin-3-ylidene)-6-methylimidazo[2,1-b]thiazole-5-carbohydrazides as Potential Anti-Proliferative Agents toward MCF-7 Breast Cancer

SKLB70326, a Novel Small-Molecule Inhibitor of Cell-Cycle Progression, Induces G0/G1 Phase Arrest and Apoptosis in Human Hepatic Carcinoma Cells

LYG-202 exerts antitumor effect on PI3K/Akt signaling pathway in human breast cancer cells

The cyclin-dependent kinase inhibitor SNS-032 induces apoptosis in breast cancer cells via depletion of Mcl-1 and X-linked inhibitor of apoptosis protein and displays antitumor activity in vivo

Synthesis and antitumor activities of novel 3-(6-aminopyridin-3-yl)benzamide derivatives: Inducing cell cycle arrest and apoptosis via AURKB transcription inhibition

[Induction of G2 /M Phase Arrest and Apoptosis of MCF-7 Cells by Novel Benzofuran Lignan Via Suppressing Cell Cycle Proteins].

Augmentation of the Anticancer Activity of CYT997 in Human Prostate Cancer by Inhibiting Src Activity

Synthesis and Mechanistic Studies of Quinolin-Chlorobenzothioate Derivatives with Proteasome Inhibitory Activity in Pancreatic Cancer Cell Lines.

SZC017, a novel oleanolic acid derivative, induces apoptosis and autophagy in human breast cancer cells

Effects of a novel tripeptide, tyroserleutide (YSL), on cell cycle progression of human hepatocellular carcinoma.

A Novel 3-Acyl Isoquinolin-1(2H)-one Induces G2 Phase Arrest, Apoptosis and GSDME-dependent Pyroptosis in Breast Cancer